Camille Samuels

Camille (Cami) Samuels is a Partner at Venrock, focusing on biotech, medical devices, and consumer health. Founded in 1969, Venrock is one of the world’s first venture capital firms, and she was its first female Partner. She currently serves on the board of Iris, Mahzi, Ocelot, Unity (UBX), and XCaliber. She previously served the boards of several exited Venrock portfolio companies, including Corvidia (sold to Novo), RegenXBio (RGNX), and Spirox (now owned by Stryker). Prior to Venrock, Cami was a Managing Director at Versant Ventures where she served on the board (or as a board observer) at many companies including Genomic Health (GHDX), Jazz (JAZZ), Kythera (KYTH/sold to Allergan), Novacardia (sold to Merck), and ParAllele (sold to Affymetrix). During her early career, Cami worked in corporate development at Genzyme, Millennium Predictive Medicine, and Tularik, and she was a management consultant at LEK Consulting. Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School (HBS), where she graduated as a Baker Scholar. She is a Henry Crown Fellow, serves on the Investment Advisory Committee of Mission Bay Capital, and serves on the HBS Global Advisory Board.